Despite the transformative impact of CAR-Tcell therapy in treatingCD19-positive hematological cancers, significantchallenges remain, particularly due to the ability of cancers to adaptto therapy by antigen escape., Here, we present bifunctionalCysCAR-T cells, which exhibit enhanced anticancer activity comparedto conventional anti-CD19 CAR-T cells. This evidence concerns the gene CD19 and hematopoietic and lymphoid cell neoplasm.